MDT Medtronic Plc

Medtronic Named a Leading Sustainability Company

Medtronic Named a Leading Sustainability Company

Strong ESG Practices Results in Inclusion on North American Dow Jones Sustainability Index (DJSI) for Twelfth Consecutive Year

DUBLIN, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced that it has been recognized as one of the world's leading companies for sustainability with its inclusion in the Dow Jones Sustainability North America Index (DJSI North America) for the twelfth consecutive year. The DJSI North America includes a select group of companies based on their performance across a variety of sustainability criteria, including economic performance, environmental stewardship, social responsibility, and corporate governance. This adds to the recognition Medtronic received earlier this year through its continued inclusion in the FTSE4Good Index Series.

Medtronic is committed to global corporate citizenship, centered on creating value and working responsibly in all facets where its business intersects with society, and this commitment aligns with the company’s long-term growth strategies of therapy innovation, globalization, and economic value. The company focuses on issues identified as most material to long-term success, including access to healthcare, product quality and patient safety, ethical business practices, responsible supply management, employee engagement and development, human rights, and environmental stewardship.

"Our focus on environmental, social and governance (ESG) reflects our deep dedication to the tenets of our Medtronic mission. That mission, set forward by our founder Earl Bakken in 1960, establishes an abiding commitment to contribute to human welfare and maintain good citizenship as a company,” said Omar Ishrak, Medtronic chairman and chief executive officer. "Not only are ESG practices aligned with our mission, but we also believe that they are directly linked to our long-term business performance and resulting value creation for our shareholders."

One example of Medtronic’s commitment to ESG is the company’s focus on Human Rights and Labor Practices. As a purpose-driven organization, Medtronic strives to conduct its business in a manner that demonstrates a respect for internationally-recognized human rights and the dignity of all people. The company’s Global Human Rights Program sits within Medtronic’s Human Resources function to ensure a consistent approach to human rights issues that may arise across its operations and supply chain. As part of the program, Medtronic conducts annual assessments of internal operations facilities for issues related to child labor, fair treatment, forced labor, freedom of association, health and safety, and remuneration.

Medtronic takes a multifaceted approach to ensuring the company’s work environment is free from discrimination based on race, ethnicity, gender, gender identity, sexual orientation, disability, religion, and other identities. Nondiscrimination is addressed in its companywide policies, including the company’s Code of Conduct and Global Human Rights and Labor Standards Policy, which also addresses workforce equality and fair employment. In FY19, Medtronic supported the Equality Act, U.S. legislation to expand the Civil Rights Act of 1964 to protect LGBTQ people against discrimination. To further demonstrate its support, Medtronic joined the Human Rights Campaign Business Coalition for the Equality Act along with more than 235 other companies.

Medtronic also continues to be recognized by the FTSE4Good Index and Corporate Responsibility Magazine's 100 Best Corporate Citizens list, both announced earlier this year. Companies in the FTSE4Good Index Series have met stringent environmental, social and governance criteria, and are positioned to capitalize on the benefits of responsible business practices. More information can be found at .

For information about Medtronic's comprehensive sustainability efforts, please visit  and access the company’s Integrated Performance Report.

Created jointly by S&P Dow Jones Indices and RobecoSAM, the Dow Jones Sustainability Indices are a family of best-in-class benchmarks for investors who have recognized that sustainable business practices are critical to generating long-term shareholder value and who wish to reflect their sustainability convictions in their investment portfolios. The family was launched in 1999 as the first global sustainability benchmark and tracks the stock performance of the world's leading companies in terms of economic, environmental and social criteria. More information about the DJSI can be found at .

About Medtronic

Medtronic plc (), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

 

Erika Winkels

Public Relations

Ryan Weispfenning

Investor Relations

EN
13/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

Medtronic, plc: Key facts and statistics - LTM October 2025

A summary company profile, detailing Medtronic plc’s business operations and financial highlights.

Medtronic Plc: 1 director

A director at Medtronic Plc sold 30,000 shares at 101.948USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch